Mizue Matsuura 1 , Masahiko Inamori 2 , * , Hiroki Endo 1 , Tetsuya Matsuura 1 , Kenji Kanoshima 1 , Yumi Inoh 1 , Yuji Fujita 1 , Shotaro Umezawa 1 , Akiko Fuyuki 1 , Shiori Uchiyama 1 , Takuma Higurashi 1 , Hidenori Ohkubo 1 , Eiji Sakai 1 , Hiroshi Iida 1 , Takashi Nonaka 1 , Seiji Futagami 3 , Akihiko Kusakabe 4 , Shin Maeda 5 , Atsushi Nakajima 1
29 December 2014
The aim of this study was to investigate the usefulness of lubiprostone for bowel preparation and as a propulsive agent in small bowel endoscopy. Six healthy male volunteers participated in this randomized, 3-way crossover study. The subjects received a 24 μg tablet of lubiprostone 60 minutes prior to the capsule ingestion for capsule endoscopy (CE) and a placebo tablet 30 minutes before the capsule ingestion (L-P regimen), a placebo tablet 60 minutes prior to CE and a 24 μg tablet of lubiprostone 30 minutes prior to CE (P-L regimen), or a placebo tablet 60 minutes prior to r CE and a placebo tablet again 30 minutes prior to CE (P-P regimen). The quality of the capsule endoscopic images and the amount of water in the small bowel were assessed on 5-point scale. The median SBTT was 178.5 (117–407) minutes in the P-P regimen, 122.5 (27–282) minutes in the L-P regimen, and 110.5 (11–331) minutes in the P-L regimen ( P = 0.042). This study showed that the use of lubiprostone significantly decreased the SBTT. We also confirmed that lubiprostone was effective for inducing water secretion into the small bowel during CE.